Summary of the Conference Call for Tigermed (泰格医药) Industry Overview - The clinical CRO (Contract Research Organization) industry is expected to maintain a double-digit growth rate of 10%-15% during the new recovery cycle after experiencing a slowdown in growth from 2023 to 2024, driven by policy support, increased local investment from multinational pharmaceutical companies, and record-high license-out transactions by domestic biopharmaceutical companies [2][5][13]. Company Positioning - Tigermed, as the leading player in China's clinical CRO market, has increased its market share from 8% in 2019 to 13% in 2023, benefiting from the strong performance of top-tier companies and the development of the SMO (Site Management Organization) industry [2][5]. - The company is actively expanding its international presence in regions such as Asia-Pacific, Europe, and the Americas, and has acquired a Japanese imaging analysis company to enhance its capabilities [2][6]. Key Trends and Changes - The supply side of the clinical CRO industry is showing signs of consolidation, with the number of sponsors decreasing by approximately 64% and the number of clinical trials declining by 72% compared to the peak in 2022 [3][7]. - Despite a relatively flat primary market in recent years, the demand for innovative drugs and equity cooperation is gradually filling the financing gap, leading to more opportunities for clinical CROs [3][13]. Impact of Multinational Companies - Multinational pharmaceutical companies are becoming significant payers in the clinical CRO industry, with 24% of phase III clinical trials in 2024 being sponsored by these companies, and the proportion of projects conducted by local CROs increasing from 23% in 2020 to 32% in 2024 [8][7]. License-Out Transactions - License-out transactions in the Chinese pharmaceutical sector have grown rapidly, with 94 transactions totaling $51.9 billion in 2024, primarily involving the U.S. as the main recipient [9]. Technological Advancements - Tigermed is embracing AI technology and remote intelligent clinical solutions to improve data quality, efficiency, and reduce costs, which is expected to enhance profitability [4][17]. Financial Performance - Tigermed's revenue and profit growth from 2023 to 2024 have been impacted by declining clinical operation order prices and some order cancellations, but the overall order prices are expected to stabilize in 2025 [28][33]. - New order growth remains positive, with a 20% year-on-year increase in new orders in the first quarter of 2025 [29]. Future Outlook - The company is well-positioned to benefit from the recovery of domestic demand and the ongoing trend of Chinese innovative drugs going global, which will drive incremental demand for Tigermed's services [18][33]. - The focus on emerging treatment areas such as cell and gene therapy (CGT) and the expansion of its service capabilities through acquisitions are expected to support sustainable growth [25][20]. Conclusion - Tigermed's strategic initiatives, including international expansion, technological innovation, and a strong market position, are expected to drive its growth in the recovering clinical CRO industry, with optimism for future performance as market conditions improve [14][33].

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 1.1816 million shares at an average price of HKD 55.9087 per share, totaling approximately HKD 66.0617 million [1] - After the purchase, E Fund's total shareholding in Tiger Med increased to 13.8033 million shares, raising its ownership percentage from 10.25% to 11.21% [1][2]

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has increased its stake in Tiger Medical (03347) by acquiring 1.1816 million shares at a price of HKD 55.9087 per share, totaling approximately HKD 66.0617 million [1] - After the increase, E Fund's total shareholding in Tiger Medical is now 13.8033 million shares, representing an ownership percentage of 11.21% [1]

Group 1 - E Fund Management Co., Ltd. increased its stake in Tiger Medical (300347) by 118.16 thousand shares at a price of 55.9087 HKD per share, totaling approximately 66.06 million HKD [1] - After the increase, the total number of shares held by E Fund is 13.8033 million, representing a holding percentage of 11.21% [1]

智通财经APP获悉，香港联交所最新数据显示，7月29日，易方达基金管理有限公司增持泰格医药 (03347)118.16万股，每股作价55.9087港元，总金额约为6606.17万港元。增持后最新持股数目为1380.33 万股，持股比例为11.21%。 ...

Group 1 - The stock prices of several biotech companies have experienced declines, with 康方生物 (09926.HK) down 5.37%, 泰格医药 (03347.HK) down 3.34%, 药明康德 (02359.HK) down 3.15%, and 君实生物 (01877.HK) down 2.64% [1]

格隆汇7月31日丨根据联交所最新权益披露资料显示，2025年7月24日，泰格医药(03347.HK)遭易方达基金管理有限公司在场内以每股均价50.0506港元减持 27.31万股，涉资约1366.88万港元。 减持后，易方达基金管理有限公司最新持股数目为1351.47万股，持股比例由11.20%下降至10.98%。 | 股份代號: | | --- | | 上市法國名稱: | | 日期 (日 / 月 / 年 | 追加内容 本文作者可以追加内容哦 ! | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | (請參閱上述 * 註 | 有投票權股 日 / 月 / 年) | | | | | | | | 解) | 份百分比 | | | | | | | | | ( % ) | | CS20250729E00287 | 易方达基金管理有限公司 | 1201(L) | ...

| 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | （請參閱上述 * 註 有投票權股 (日 / 月 / 年） | | | | | | | | 解) 份百分比 | | | | | | | | ( % ) | | CS20250729E00287 | 易方达基金管理有限公司 | 1201(L) | | 273,100(L | HKD 50.0506 | 13,514,700(L) 10.98(L)24/07/2025 | 减持后，易方达基金管理有限公司最新持股数目为1351.47万股，持股比例由11.20%下降至10.98%。 | 股份代號: | 03347 | | --- | --- | | 上市法國名稱: | 杭州泰格醫藥科技股份有 | | 日期 (日 / 月 / 年): | 30/06/2025 - 31/07/2025 | 格隆汇7月31日丨根据联交所最新权益 ...

7月29日，受"CXO一哥"药明康德业绩回暖的提振，整个CXO板块沸腾。其中，港股泰格医药盘中大涨 超10%，拉长时间线来看，自4月9日的股价低点以来，公司股价累计大涨136%。泰格医药A股盘中也涨 超13%，股价最高达71.71元/股，创2025年以来新高。 值得一提的是，身为CRO龙头的泰格医药酷爱投资，从参投基金做LP、一级市场直投到二级市场"炒 股"，公司均有涉猎。 而随着创新药牛市的到来，泰格医药在一二级市场投资的创新药公司有望迎来估值提升，公司也能"分 一杯羹"。7月17日，泰格医药刚公告公司持有的礼新医药股份被中国生物制药收购。今年4月刚登陆港 股的映恩生物背后，也有泰格医药的身影。 回溯以往，泰格医药的投资收益一度占公司归母净利润的一半以上，成功"反哺"公司的CRO业务。但需 要注意的是，这种业务模式受行业景气度影响较大，"常在河边走，哪有不湿鞋"，2024年，公司归母净 利润暴跌近80%，其中就有投资收益下滑的影响。 泰格医药4个月涨136% 7月29日，A股CRO板块大涨4%，其中泰格医药盘中涨超13%，股价最高达71.71元/股，创2025年以来新 高。截至收盘，涨幅回落至8.8%，报6 ...

智通财经APP获悉，香港联交所最新资料显示，7月24日，易方达基金减持泰格医药(03347)27.31万股， 每股作价50.0506港元，总金额约为1366.88万港元。减持后最新持股数目为1351.47万股，持股比例为 10.98%。 ...